Research programme: AMPK activators - NovaTarg Therapeutics

Drug Profile

Research programme: AMPK activators - NovaTarg Therapeutics

Alternative Names: NT 1044

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovaTarg Therapeutics
  • Class Antineoplastics; Biguanides
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Hepatitis C
  • Research Dengue; Fatty liver
  • No development reported Polycystic kidney disease; Type 2 diabetes mellitus

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for research development in Polycystic-kidney-disease in USA
  • 28 Dec 2017 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA
  • 25 May 2016 Early research in Fatty liver and Dengue in USA (unspecified route) (Novatarg Therapeutics website, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top